APLS Articles, Apellis Pharmaceuticals Inc. - From 09/02/23

NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds inves...

NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. ("Ape...

NEW YORK, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders ...

CEDARHURST, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of...

LOS ANGELES, Aug. 30, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on ...

WALTHAM, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS), a global biopharmaceutical company and leader i...

NEW ORLEANS, Aug. 29, 2023 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until Octob...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The Por...

Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagshi...

NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a ...